Profit Warning Alert | 2026-04-23 | Quality Score: 92/100
We offer stock analysis and market commentary focused on earnings outcomes and sector-level movements.
Johnson & Johnson (NYSE: JNJ), the diversified global healthcare leader operating across pharmaceuticals, medical technology, and consumer health with leading treatments in immunology, oncology, neuroscience and cardiovascular care, has emerged as a top deep-value play amid a broad 2026 selloff in t
Live News
As of April 23, 2026, 11:54 UTC, Johnson & Johnson (NYSE: JNJ) was featured as a top bullish pick on Jim Cramer’s *Mad Money* program, with Cramer announcing that his Charitable Trust had initiated a position in the stock during the ongoing sector-wide pullback. Cramer noted that pharma is currently deeply out of favor with market participants, who have rotated heavily into high-growth AI and cyclical industrial names so far this year, creating a rare opportunity to buy high-quality healthcare a
Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryAccess to multiple perspectives can help refine investment strategies. Traders who consult different data sources often avoid relying on a single signal, reducing the risk of following false trends.Scenario analysis based on historical volatility informs strategy adjustments. Traders can anticipate potential drawdowns and gains.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryThe interplay between macroeconomic factors and market trends is a critical consideration. Changes in interest rates, inflation expectations, and fiscal policy can influence investor sentiment and create ripple effects across sectors. Staying informed about broader economic conditions supports more strategic planning.
Key Highlights
1. **Valuation Profile**: JNJ currently trades at 13.2x forward 12-month price-to-earnings (P/E), a 22% discount to its 5-year historical average of 16.9x, and an 18% discount to the large-cap pharma peer group average of 16.1x. The stock also offers a 3.1% annual dividend yield, with 59 consecutive years of dividend increases, earning it Dividend King status, one of only 48 U.S. public companies to hold the designation. 2. **Icotyde Catalyst**: Consensus sell-side estimates project Icotyde will
Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryTraders frequently use data as a confirmation tool rather than a primary signal. By validating ideas with multiple sources, they reduce the risk of acting on incomplete information.Some traders rely on patterns derived from futures markets to inform equity trades. Futures often provide leading indicators for market direction.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryIncorporating sentiment analysis complements traditional technical indicators. Social media trends, news sentiment, and forum discussions provide additional layers of insight into market psychology. When combined with real-time pricing data, these indicators can highlight emerging trends before they manifest in broader markets.
Expert Insights
Cramer’s bullish call on JNJ aligns with core portfolio construction principles he cited from his tenure at Goldman Sachs, noting that “assets do not appreciate in unison, and defensive exposure is critical to mitigating drawdowns in growth-heavy portfolios.” With a 5-year beta of 0.62, JNJ is 38% less volatile than the broader S&P 500, making it an ideal hedge for investors holding concentrated positions in high-beta AI and tech stocks that have led 2026 market gains. That said, investors should weigh material downside risks before initiating a position. JNJ’s top-selling immunology drug Stelara loses U.S. exclusivity in 2027, with consensus estimates projecting the loss of $2.1 billion in annual revenue by 2028 before Icotyde and other pipeline assets can offset the decline. Additionally, proposed U.S. drug pricing reforms could compress margins for JNJ’s top 10 selling products by an estimated 7% to 9% if passed in their current form. Consensus analyst ratings remain largely bullish on JNJ, with 18 of 24 covering analysts assigning a Buy or Strong Buy rating, and a weighted average 12-month price target of $187, implying 21% upside from JNJ’s April 23 closing price of $154.50. For investors seeking higher short-term upside, as noted in recent market analysis, select undervalued AI plays positioned to benefit from onshoring trends and Trump-era tariff policies may offer higher risk-adjusted returns, though these assets carry far higher volatility and drawdown risk than JNJ. Overall, JNJ represents a high-quality defensive play for long-term investors with moderate risk tolerance, and the current sector selloff offers a rare entry point to one of the U.S.’s most consistent operational performers. For growth-focused investors, a 5% to 10% portfolio allocation to JNJ can provide meaningful downside protection without sacrificing long-term total return potential, balancing exposure to high-growth segments that dominate current market momentum. (Word count: 1172) Disclosure: No holdings in JNJ or mentioned AI securities as of publication.
Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryHistorical trends provide context for current market conditions. Recognizing patterns helps anticipate possible moves.Investors often monitor sector rotations to inform allocation decisions. Understanding which sectors are gaining or losing momentum helps optimize portfolios.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryStress-testing investment strategies under extreme conditions is a hallmark of professional discipline. By modeling worst-case scenarios, experts ensure capital preservation and identify opportunities for hedging and risk mitigation.